William Weiss, Director of Pre-Clinical Services, **University of North Texas Health Science Center**
Bill Weiss is currently the Director of Preclinical Services at the University of North Texas Health Science Center in Fort Worth. He uses his 33 years of experience and expertise in infectious disease research to direct the evaluations of antibacterial agents, including established models of both acute and chronic bacterial infections in several different animal species as well as pharmacokinetic studies and HPLC or LCMS analysis in collaboration with large pharmaceutical companies, the biotech industry as well as academia. Prior to this, he was Director of Drug Evaluation at Cumbre Pharmaceuticals Inc. His responsibilities included animal efficacy models, pharmacology and all pre-clinical microbiology research and development efforts focused on the discovery and development of new antimicrobial agents. Previously, he was a Group Leader in Infectious Disease Discovery Research at Wyeth Research, Lederle Laboratories and Schering-Plough and has held various positions of responsibility in antibacterial, antiviral and antifungal discovery research. He has worked on numerous antibacterial programs including the development of the marketed products, Suprax, Zosyn and Tygacil. His expertise encompasses the development and evaluation of animal models of infectious disease as well as pharmacokinetic and pharmacodynamic analysis. He has authored / co-authored over 80 research presentations and journal articles.